Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

ABSTRACT:

SUBMITTER: Charalampous C 

PROVIDER: S-EPMC10711005 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature